448 Matching Annotations
  1. Aug 2022
    1. Lucas, C., Vogels, C. B. F., Yildirim, I., Rothman, J. E., Lu, P., Monteiro, V., Gelhausen, J. R., Campbell, M., Silva, J., Tabachikova, A., Peña-Hernandez, M. A., Muenker, M. C., Breban, M. I., Fauver, J. R., Mohanty, S., Huang, J., Shaw, A. C., Ko, A. I., Omer, S. B., … Iwasaki, A. (2021). Impact of circulating SARS-CoV-2 variants on mRNA vaccine-induced immunity. Nature, 1–9. https://doi.org/10.1038/s41586-021-04085-y

    1. Krause, P. R., Fleming, T. R., Peto, R., Longini, I. M., Figueroa, J. P., Sterne, J. A. C., Cravioto, A., Rees, H., Higgins, J. P. T., Boutron, I., Pan, H., Gruber, M. F., Arora, N., Kazi, F., Gaspar, R., Swaminathan, S., Ryan, M. J., & Henao-Restrepo, A.-M. (2021). Considerations in boosting COVID-19 vaccine immune responses. The Lancet, 4. https://doi.org/10.1016/S0140-6736(21)02046-8

  2. May 2022
  3. Apr 2022
    1. Tom Wenseleers. (2022, January 23). @HarrySpoelstra @trvrb @CorneliusRoemer @JosetteSchoenma BA.2 has a growth rate advantage over BA.1 of ca 0.11/day. That’s quite sizeable. If it would have the same short generation time as BA.1 of 2.2 days it would imply a ca.1.3x higher transmissibility, due to higher contagiousness or immune escape. Https://t.co/X8TcWJ4pXQ [Tweet]. @TWenseleers. https://twitter.com/TWenseleers/status/1485375883066101763

    1. Prof Francois Balloux [@BallouxFrancois]. (2021, December 9). This may have sounded somewhat naïve in early 2020, but by now, I would have expected that anyone with an interest in covid-19 might have acquired some basic notions in infectious disease epidemiology. 1/ [Tweet]. Twitter. https://twitter.com/BallouxFrancois/status/1469063480334561285

    1. Pérez-Then, E., Lucas, C., Monteiro, V. S., Miric, M., Brache, V., Cochon, L., Vogels, C. B. F., Cruz, E. D. la, Jorge, A., Santos, M. D. los, Leon, P., Breban, M. I., Billig, K., Yildirim, I., Pearson, C., Downing, R., Gagnon, E., Muyombwe, A., Razeq, J., … Iwasaki, A. (2021). Immunogenicity of heterologous BNT162b2 booster in fully vaccinated individuals with CoronaVac against SARS-CoV-2 variants Delta and Omicron: The Dominican Republic Experience (p. 2021.12.27.21268459). medRxiv. https://doi.org/10.1101/2021.12.27.21268459

    1. Paul Bieniasz [@PaulBieniasz]. (2021, December 12). It is time to discard the notion that two doses of mRNA means “fully vaccinated” It is time to discard the notion that prior SARS-CoV-2 infection means you don’t need to be vaccinated. [Tweet]. Twitter. https://twitter.com/PaulBieniasz/status/1470041859053563906

    1. Dr Nisreen Alwan 🌻. (2021, March 14). Exactly a year ago we wrote this letter in the Times. We were gobsmacked! We just didn’t understand what the government was basing all its decisions on including stopping testing and the herd immunity by natural infection stuff. We wanted to see the evidence backing them. [Tweet]. @Dr2NisreenAlwan. https://twitter.com/Dr2NisreenAlwan/status/1371168531669258242

  4. Mar 2022
    1. Mia Malan. (2021, November 25). [Thread] What is the potential impact of the new B.1.1.529 #COVID19 variant? @rjlessells: 1. It’s relatively simple to detect some B.1.1.529 cases, as it’s possible to use PCR tests to do this in some cases 2. B.1.1.529 = has many mutations across different parts of the virus https://t.co/ytktqLzJUi [Tweet]. @miamalan. https://twitter.com/miamalan/status/1463846528578109444

    1. george davey smith. (2021, December 28). Omicron is illustrating “herd immunity” as how it was introduced: A relative concept, that reduces the adverse outcome of infections within populations, not as an absolute threshold that stopped transmission; as @bmj_latest #covidunknowns webinar explains https://t.co/t8nPeL9V8r [Tweet]. @mendel_random. https://twitter.com/mendel_random/status/1475821583331700739

  5. Feb 2022
    1. Yamasoba, D., Kimura, I., Nasser, H., Morioka, Y., Nao, N., Ito, J., Uriu, K., Tsuda, M., Zahradnik, J., Shirakawa, K., Suzuki, R., Kishimoto, M., Kosugi, Y., Kobiyama, K., Hara, T., Toyoda, M., Tanaka, Y. L., Butlertanaka, E. P., Shimizu, R., … Sato, K. (2022). Virological characteristics of SARS-CoV-2 BA.2 variant (p. 2022.02.14.480335). bioRxiv. https://doi.org/10.1101/2022.02.14.480335

    1. Peña-Hernández, M. A., Klein, J., Malik, A. A., Coppi, A., Kalinich, C., Vogels, C. B. F., Silva, J., Initiative, Y. S.-C.-2 G. S., Peaper, D. R., Landry, M.-L., Wilen, C., Grubaugh, N. D., Schulz, W., Omer, S. B., & Iwasaki, A. (2022). Comparison of infectious SARS-CoV-2 from the nasopharynx of vaccinated and unvaccinated individuals (p. 2021.12.28.21268460). medRxiv. https://doi.org/10.1101/2021.12.28.21268460

    1. Afkhami, S., D’Agostino, M. R., Zhang, A., Stacey, H. D., Marzok, A., Kang, A., Singh, R., Bavananthasivam, J., Ye, G., Luo, X., Wang, F., Ang, J. C., Zganiacz, A., Sankar, U., Kazhdan, N., Koenig, J. F. E., Phelps, A., Gameiro, S. F., Tang, S., … Xing, Z. (2022). Respiratory mucosal delivery of next-generation COVID-19 vaccine provides robust protection against both ancestral and variant strains of SARS-CoV-2. Cell, S0092867422001453. https://doi.org/10.1016/j.cell.2022.02.005

    1. Trevor Bedford. (2022, January 28). Omicron viruses can be divided into two major groups, referred to as PANGO lineages BA.1 and BA.2 or @nextstrain clades 21K and 21L. The vast majority of globally sequenced Omicron have been 21K (~630k) compared a small minority of 21L (~18k), but 21L is gaining ground. 1/15 [Tweet]. @trvrb. https://twitter.com/trvrb/status/1487105396879679488

  6. Jan 2022
    1. Tom Wenseleers. (2022, January 30). Seems that the second Omicron subvariant BA.2 may soon be about to cause cases to start rising again in South Africa... Or at least to stop the decline in new infections. Shows how fast immunity wanes & evolution can catch up. Https://t.co/3y4xqPgZ0L [Tweet]. @TWenseleers. https://twitter.com/TWenseleers/status/1487919837670219781